Warning! GuruFocus detected
3 Severe warning signs
with V7B.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Assembly Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US0453961080
Description
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 36.28 | |||||
| Equity-to-Asset | 0.28 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -9.33 | |||||
| Beneish M-Score | 0.07 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 39.9 | |||||
| 3-Year EBITDA Growth Rate | 33 | |||||
| 3-Year EPS without NRI Growth Rate | 35.3 | |||||
| 3-Year FCF Growth Rate | 31.7 | |||||
| 3-Year Book Growth Rate | -52.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 7.86 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 21.65 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.21 | |||||
| 9-Day RSI | 37.66 | |||||
| 14-Day RSI | 37.15 | |||||
| 3-1 Month Momentum % | -15.53 | |||||
| 6-1 Month Momentum % | -3.69 | |||||
| 12-1 Month Momentum % | 7.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.42 | |||||
| Quick Ratio | 2.42 | |||||
| Cash Ratio | 2.34 | |||||
| Days Sales Outstanding | 0.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -23 | |||||
| Shareholder Yield % | -36.94 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -159.26 | |||||
| Net Margin % | -140.87 | |||||
| FCF Margin % | -177.49 | |||||
| ROE % | -119.76 | |||||
| ROA % | -33.96 | |||||
| ROIC % | -110.67 | |||||
| 3-Year ROIIC % | 2426.88 | |||||
| ROC (Joel Greenblatt) % | -1846.79 | |||||
| ROCE % | -59.33 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.21 | |||||
| PB Ratio | 2.35 | |||||
| Price-to-Tangible-Book | 2.35 | |||||
| EV-to-EBIT | 0.64 | |||||
| EV-to-EBITDA | 0.64 | |||||
| EV-to-Revenue | -1.02 | |||||
| EV-to-Forward-Revenue | 0.01 | |||||
| EV-to-FCF | 0.53 | |||||
| Price-to-GF-Value | 0.56 | |||||
| Price-to-Net-Current-Asset-Value | 2.64 | |||||
| Price-to-Net-Cash | 2.98 | |||||
| Earnings Yield (Greenblatt) % | 155.58 | |||||
| FCF Yield % | -66.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Assembly Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 26.442 | ||
| EPS (TTM) (€) | -6.226 | ||
| Beta | 0.77 | ||
| 3-Year Sharpe Ratio | 0.07 | ||
| 3-Year Sortino Ratio | 0.11 | ||
| Volatility % | 30.72 | ||
| 14-Day RSI | 37.15 | ||
| 14-Day ATR (€) | 0.43693 | ||
| 20-Day SMA (€) | 10.464 | ||
| 12-1 Month Momentum % | 7.92 | ||
| 52-Week Range (€) | 9.36 - 17.95 | ||
| Shares Outstanding (Mil) | 7.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Assembly Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Assembly Biosciences Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Assembly Biosciences Inc Frequently Asked Questions
What is Assembly Biosciences Inc(FRA:V7B)'s stock price today?
The current price of FRA:V7B is €9.82. The 52 week high of FRA:V7B is €17.95 and 52 week low is €9.36.
When is next earnings date of Assembly Biosciences Inc(FRA:V7B)?
The next earnings date of Assembly Biosciences Inc(FRA:V7B) is 2025-05-08 Est..
Does Assembly Biosciences Inc(FRA:V7B) pay dividends? If so, how much?
Assembly Biosciences Inc(FRA:V7B) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers